Drug Trial Radar · NCT03848286
KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma
Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
153
Actual
Start
Mar 6, 2019
Primary completion
Jul 13, 2021
Study completion Jan 13, 2022
Sponsor
- Lead sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 20, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is to evaluate the efficacy of KL-A167 injection in subjects with recurrent/metastatic Nasopharyngeal Carcinoma, as measured by Overall Response Rate (ORR) per the Response Evaluation Criteria in Solid Tumors RECIST Version 1.1
Conditions
- Nasopharyngeal Carcinoma
- Recurrent or Metastatic
Interventions
KL-A167 InjectionDrug
KL-A167 900 mg intravenously (IV) every-2-weeks (Q2W)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) assess by Independent Review Committee (IRC)Time frame: from first patient first visit to 12 month after last patient first dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.